Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 4943
  • Home
  • Print this page
  • Email this page
Year : 1997  |  Volume : 45  |  Issue : 2  |  Page : 109-113

Primary argon laser trabeculoplasty vs pilocarpine 2% in open angle glaucoma : Two years follow-up study

Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
A Sharma
Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 9475029

Rights and PermissionsRights and Permissions

In a prospective study, the efficacy of argon laser trabeculoplasty (ALT) was evaluated and compared with pilocarpine 2% as primary treatment in newly diagnosed primary open angle glaucoma (POAG). Out of 38 patients with POAG included in this study, one eye each of 36 patients underwent ALT, and one eye each of 26 patients received pilocarpine 2% every 8 hours. The mean pre-treatment IOP was 25.484.13 mmHg in ALT group and 24.473.51 mmHg in the pilocarpine group. The mean post treatment IOP at 2 year follow was 18.22.55 mmHg in ALT group and 18.272.22 mmHg in the pilocarpine group. Post treatment IOP was significantly lower than pre-treatment IOP in both ALT and pilocarpine groups. The post treatment fall in IOP showed no significant difference in ALT versus pilocarpine 2% at various follow up intervals (p>0.05). This study showed equal efficacy of ALT and pilocarpine 2% as initial therapy of POAG.

[FULL TEXT] [PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded4    
    Comments [Add]    

Recommend this journal